Lomecel-B medicinal signaling cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 211 | Hypoplastic left heart syndrome | 1 |
211. Hypoplastic left heart syndrome
Clinical trials : 22 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04925024 (ClinicalTrials.gov) | June 25, 2021 | 8/6/2021 | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. | Hypoplastic Left Heart Syndrome | Biological: Lomecel-B medicinal signaling cells | Ann & Robert H Lurie Children's Hospital of Chicago | National Heart, Lung, and Blood Institute (NHLBI);The University of Texas Health Science Center, Houston;Longeveron Inc. | Recruiting | N/A | 12 Months | All | 38 | Phase 2 | United States |